These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19155567)

  • 21. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults.
    Larsen RL; Jakacki RI; Vetter VL; Meadows AT; Silber JH; Barber G
    Am J Cardiol; 1992 Jul; 70(1):73-7. PubMed ID: 1615874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
    Sadurska E
    Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating survivors of pediatric cancer.
    Bhatia S; Landier W
    Cancer J; 2005; 11(4):340-54. PubMed ID: 16197724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors.
    Abosoudah I; Greenberg ML; Ness KK; Benson L; Nathan PC
    Pediatr Blood Cancer; 2011 Sep; 57(3):467-72. PubMed ID: 21280201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.
    Leger K; Slone T; Lemler M; Leonard D; Cochran C; Bowman WP; Bashore L; Winick N
    Pediatr Blood Cancer; 2015 Jan; 62(1):123-7. PubMed ID: 25176022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer survivorship: a pediatric perspective.
    Landier W; Bhatia S
    Oncologist; 2008 Nov; 13(11):1181-92. PubMed ID: 18987046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac Outcomes in Survivors of Pediatric and Adult Cancers.
    Nathan PC; Amir E; Abdel-Qadir H
    Can J Cardiol; 2016 Jul; 32(7):871-80. PubMed ID: 27179545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late Cardiotoxicity: Issues for Childhood Cancer Survivors.
    Akam-Venkata J; Franco VI; Lipshultz SE
    Curr Treat Options Cardiovasc Med; 2016 Jul; 18(7):47. PubMed ID: 27230282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
    Hudson MM; Rai SN; Nunez C; Merchant TE; Marina NM; Zalamea N; Cox C; Phipps S; Pompeu R; Rosenthal D
    J Clin Oncol; 2007 Aug; 25(24):3635-43. PubMed ID: 17704413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
    Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
    Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
    J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
    Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
    Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study.
    Haddy N; Diallo S; El-Fayech C; Schwartz B; Pein F; Hawkins M; Veres C; Oberlin O; Guibout C; Pacquement H; Munzer M; N'Guyen TD; Bondiau PY; Berchery D; Laprie A; Scarabin PY; Jouven X; Bridier A; Koscielny S; Deutsch E; Diallo I; de Vathaire F
    Circulation; 2016 Jan; 133(1):31-8. PubMed ID: 26487757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.
    Zerra P; Cochran TR; Franco VI; Lipshultz SE
    Expert Opin Pharmacother; 2013 Aug; 14(11):1497-513. PubMed ID: 23705955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
    Wexler LH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.